PCVX

Price (1 year)

Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.

Recent Form 4

Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.

Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.

Congressional trades

STOCK Act disclosures (90-day window)

Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.

Recent trades

Signal

Neutral signalScored 2026-10-26 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.

PCVX shows a strong liquidity position (score 85) but near-zero fundamental momentum (score 20) as a pre-revenue biotech with persistent cash burn and no path to profitability.

The first sentence of the analysis written for PCVX on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.

Recent news

• 2026-10-18 Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company.
• 2026-10-14 Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
• 2026-10-12 Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 million of 1.50% convertible senior notes due 2032. The notes are senior unsecured obligations. The initial conversion rate is 11.1607 shares per $1,000 principal amount, or about $89.60 a share. The company also sold 7,412,500 shares of common stock
• 2026-10-08 Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company''s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the completion of the transaction, the executive vice president owned 145,435 shares in the
• 2026-10-06 Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.
• 2026-10-06 Vaxcyte: ''Strong Buy'' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 Vaxcyte remains a ''Strong Buy'' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS-2 and OPUS-3 phase 3 data for VAX-31 in adults in the 1st half of 2027 and phase 2 infant data. VAX-31 targets broader pneumococcal strain coverage versus current vaccines, addressing emerging serotypes and aiming for 95% adult IPD coverage.
• 2026-10-06 Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday after Needham and Company LLC raised their price target on the stock from $110.00 to $122.00. Needham and Company LLC currently has a buy rating on the stock. 1,142,393 shares changed hands during mid-day trading, a decline of 21% from the
• 2026-10-06 Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Vaxcyte (NASDAQ: PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults. The randomized, double-blind, active-controlled study enrolled 4,047 U.S. adults, including 3,572 participants aged 50 and older and 475 participants aged 18 to 49. VAX-31 is being developed to prevent invasive
• 2026-10-05 Vaxcyte''s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
• 2026-10-05 Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to grant the underwriters a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments. The completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when either offering may be completed, or as to the actual size or terms of either offering.

Market snapshot

Financial ratios

Sparkline shows each ratio oldest → newest (left → right).

How the latest year compares

For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower

Key metrics

Change by theme

Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.

Change over 1 year

Change over 5 years

Employee count

Peer market caps